MVP Stock Overview
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$4.81|
|52 Week High||AU$7.29|
|52 Week Low||AU$3.21|
|1 Month Change||-2.43%|
|3 Month Change||33.61%|
|1 Year Change||-31.77%|
|3 Year Change||13.71%|
|5 Year Change||15.07%|
|Change since IPO||902.08%|
Recent News & Updates
|MVP||AU Pharmaceuticals||AU Market|
Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -9.8% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned 11.4% over the past year.
|MVP Average Weekly Movement||7.6%|
|Pharmaceuticals Industry Average Movement||8.9%|
|Market Average Movement||8.3%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||3.6%|
Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MVP's weekly volatility (8%) has been stable over the past year.
About the Company
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain in trauma; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, resuscitation kits, oxygen therapy masks, and resuscitators.
Medical Developments International Fundamentals Summary
|MVP fundamental statistics|
Is MVP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MVP income statement (TTM)|
|Cost of Revenue||AU$6.17m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.18|
|Net Profit Margin||-49.72%|
How did MVP perform over the long term?See historical performance and comparison
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$4.81) is trading above our estimate of fair value (A$0.16)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: MVP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MVP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (5x) compared to the AU Pharmaceuticals industry average (3.2x).
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MVP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MVP's is expected to become profitable in the next 3 years.
Revenue vs Market: MVP's revenue (30.5% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: MVP's revenue (30.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (1.8%).
How has Medical Developments International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP is currently unprofitable.
Growing Profit Margin: MVP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 74.2% per year.
Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.4%).
Return on Equity
High ROE: MVP has a negative Return on Equity (-18.4%), as it is currently unprofitable.
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$47.4M) exceed its short term liabilities (A$7.0M).
Long Term Liabilities: MVP's short term assets (A$47.4M) exceed its long term liabilities (A$24.9M).
Debt to Equity History and Analysis
Debt Level: MVP is debt free.
Reducing Debt: MVP has no debt compared to 5 years ago when its debt to equity ratio was 2.5%.
Debt Coverage: MVP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MVP has no debt, therefore coverage of interest payments is not a concern.
What is Medical Developments International current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brent MacGregor (57 yo)
Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...
CEO Compensation Analysis
Compensation vs Market: Brent's total compensation ($USD943.23K) is above average for companies of similar size in the Australian market ($USD544.14K).
Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.
Experienced Management: MVP's management team is considered experienced (2.3 years average tenure).
Experienced Board: MVP's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MVP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.
Medical Developments International Limited's employee growth, exchange listings and data sources
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$338.580m
- Shares outstanding: 71.28m
- Website: https://medicaldev.com
Number of Employees
- Medical Developments International Limited
- 4 Caribbean Drive
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 07:02|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.